PFC
ZVRA icon

Phocas Financial Corp’s Zevra Therapeutics ZVRA Stock Holding History

Phocas Financial Corp’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.24M Buy
295,907
+136,484
+86% +$1.52M 0.59% 73
2026
Q1 		$1.49M Buy
+159,423
New +$1.44M 0.23% 118

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Phocas Financial Corp's ZVRA Position: Q2 2026 in Review

Phocas Financial Corp increased its Zevra Therapeutics (ZVRA) stake by 86% in Q2 2026, buying an estimated $1.52M and bringing the position to 295,907 shares worth $4.24M. The position accounts for 0.59% of the portfolio, ranked #73.

Phocas Financial Corp first reported a position in ZVRA in Q1 2026 and has held it in 2 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Phocas Financial Corp held 295,907 shares of Zevra Therapeutics worth $4.24M as of Q2 2026.
  • Phocas Financial Corp bought 136,484 Zevra Therapeutics shares in Q2 2026, an estimated $1.52M.
  • Zevra Therapeutics made up 0.59% of Phocas Financial Corp's portfolio in Q2 2026, its #73 holding.
  • Phocas Financial Corp first reported a position in Zevra Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Phocas Financial Corp's 13F filing for Q2 2026, filed 31 Jul 2026.